Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care

Timecodes:

ARANOTE trial- 43:32-48:08

Rationale of using ultra-low PSA thresholds- 48:08-51:25

Understanding the prognostic value of ultra-low PSA results- 51:25-55:20

Ultralow PSA levels in the TITAN trial- 55:20-58:24